These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 23994973)

  • 21. Long-term efficacy of early infliximab-induced remission for refractory uveoretinitis associated with Behçet's disease.
    Keino H; Watanabe T; Nakayama M; Komagata Y; Fukuoka K; Okada AA
    Br J Ophthalmol; 2021 Nov; 105(11):1525-1533. PubMed ID: 32972915
    [TBL] [Abstract][Full Text] [Related]  

  • 22. An open-label, prospective, single-arm study of switching from infliximab to cyclosporine for refractory uveitis in patients with Behçet's disease in long-term remission.
    Ida Y; Takeuchi M; Ishihara M; Shibuya E; Yamane T; Hasumi Y; Kawano S; Kimura I; Mizuki N
    Jpn J Ophthalmol; 2021 Nov; 65(6):843-848. PubMed ID: 34586526
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Poor prognostic factors in patients with newly diagnosed intestinal Adamantiades-Behçet's disease in the Shanghai Adamantiades-Behçet's disease database: a prospective cohort study.
    Zhang L; Tian Y; Ye JF; Lin CH; Guan JL
    Orphanet J Rare Dis; 2019 Nov; 14(1):274. PubMed ID: 31779646
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Behçet's disease; A rare refractory patient with vena cava superior syndrome treated with infliximab: a case report and review of the literature.
    Uyaroglu OA; Erden A; Kilic L; Peynircioğlu B; Karadag O; Kalyoncu U
    Acta Clin Belg; 2019 Oct; 74(5):364-369. PubMed ID: 30220250
    [No Abstract]   [Full Text] [Related]  

  • 25. Remission of intestinal Behçet's disease treated with anti-tumor necrosis factor alpha monoclonal antibody (Infliximab).
    Lee JH; Kim TN; Choi ST; Jang BI; Shin KC; Lee SB; Shim YR
    Korean J Intern Med; 2007 Mar; 22(1):24-7. PubMed ID: 17427642
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Early infliximab trough levels are associated with persistent remission in pediatric patients with inflammatory bowel disease.
    Singh N; Rosenthal CJ; Melmed GY; Mirocha J; Farrior S; Callejas S; Tripuraneni B; Rabizadeh S; Dubinsky MC
    Inflamm Bowel Dis; 2014 Oct; 20(10):1708-13. PubMed ID: 25153505
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Infliximab Biosimilar (Remsima™) in Therapy of Inflammatory Bowel Diseases Patients: Experience from One Tertiary Inflammatory Bowel Diseases Centre.
    Kolar M; Duricova D; Bortlik M; Hruba V; Machkova N; Mitrova K; Malickova K; Lukas M; Lukas M
    Dig Dis; 2017; 35(1-2):91-100. PubMed ID: 28147356
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and Safety of Infliximab in Intestinal Behçet's Disease: A Multicenter, Phase 3 Study (BEGIN).
    Cheon JH; Kim HS; Han DS; Kim SK; Shin SJ; Kim JS; Ye BD; Song GA; Lee Y; Kim Y; Lee Y; Kim WH;
    Gut Liver; 2023 Sep; 17(5):777-785. PubMed ID: 36578194
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term safety and efficacy of infliximab therapy in refractory uveitis due to Behçet's disease.
    Abu El-Asrar AM; Abboud EB; Aldibhi H; Al-Arfaj A
    Int Ophthalmol; 2005 Jun; 26(3):83-92. PubMed ID: 17031510
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Biosimilar infliximab for Behçet's syndrome: a case series.
    Dincses E; Esatoglu SN; Ozguler Y; Uygunoglu U; Hamuryudan V; Seyahi E; Melikoglu M; Fresko I; Ucar D; Ozyazgan Y; Kutlubay Z; Mat MC; Yurdakul S; Siva A; Hatemi G
    Clin Exp Rheumatol; 2019; 37 Suppl 121(6):111-115. PubMed ID: 31856937
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-term outcome of treatment with infliximab in pediatric-onset Crohn's disease: a population-based study.
    Crombé V; Salleron J; Savoye G; Dupas JL; Vernier-Massouille G; Lerebours E; Cortot A; Merle V; Vasseur F; Turck D; Gower-Rousseau C; Lémann M; Colombel JF; Duhamel A
    Inflamm Bowel Dis; 2011 Oct; 17(10):2144-52. PubMed ID: 21287665
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Induction of ocular Behçet's disease remission after short-term treatment with infliximab: a case series of 11 patients with a follow-up from 4 to 16 years.
    Sfikakis PP; Arida A; Ladas DS; Markomichelakis N
    Clin Exp Rheumatol; 2019; 37 Suppl 121(6):137-141. PubMed ID: 31856941
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Infliximab therapy in Behçet's uveitis.
    Alizadegan F; Yalcinbayir O; Ucan Gunduz G; Pehlivan Y
    J Fr Ophtalmol; 2022 Nov; 45(9):1036-1041. PubMed ID: 36150991
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pre-existing IgG antibodies cross-reacting with the Fab region of infliximab predict efficacy and safety of infliximab therapy in inflammatory bowel disease.
    Steenholdt C; Palarasah Y; Bendtzen K; Teisner A; Brynskov J; Teisner B; Nielsen CH
    Aliment Pharmacol Ther; 2013 Jun; 37(12):1172-83. PubMed ID: 23650912
    [TBL] [Abstract][Full Text] [Related]  

  • 35. C-reactive protein level at 2 weeks following initiation of infliximab induction therapy predicts outcomes in patients with ulcerative colitis: a 3 year follow-up study.
    Iwasa R; Yamada A; Sono K; Furukawa R; Takeuchi K; Suzuki Y
    BMC Gastroenterol; 2015 Aug; 15():103. PubMed ID: 26271624
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long-term remission of ocular and extraocular manifestations in Behçet's disease using infliximab.
    Handa T; Tsunekawa H; Yoneda M; Watanabe D; Mukai T; Yamamura M; Iwaki M; Zako M
    Clin Exp Rheumatol; 2011; 29(4 Suppl 67):S58-63. PubMed ID: 21968238
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and safety of infliximab in treating patients with ulcerative colitis: experiences from a single medical center in southern China.
    Zhou YL; Xie S; Wang P; Zhang T; Lin MY; Tan JS; Zhi FC; Jiang B; Chen Y
    J Dig Dis; 2014 Sep; 15(9):483-90. PubMed ID: 24828856
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Remission induction, maintenance, and endoscopic outcome with oral 5-aminosalicylic acid in intestinal Behçet's disease.
    Kinoshita H; Nishioka H; Ikeda A; Ikoma K; Sameshima Y; Ohi H; Tatsuno M; Kouyama J; Kawamoto C; Mitsui T; Tamura Y; Hashimoto Y; Nishio M; Ogashiwa T; Saigusa Y; Maeda S; Kimura H; Kunisaki R; Koike K
    J Gastroenterol Hepatol; 2019 Nov; 34(11):1929-1939. PubMed ID: 31017728
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Remission of Behcet's disease with anti-tumor necrosis factor monoclonal antibody therapy: a case report.
    Gulli S; Arrigo C; Bocchino L; Morgante L; Sangari D; Castagna I; Bagnato GF
    BMC Musculoskelet Disord; 2003 Aug; 4():19. PubMed ID: 12946278
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Elective switching from infliximab to adalimumab in stable Crohn's disease.
    Hoentjen F; Haarhuis BJ; Drenth JP; de Jong DJ
    Inflamm Bowel Dis; 2013; 19(4):761-6. PubMed ID: 23446337
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.